Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the ...

The e-vehicle maker's quarterly delivery figures are expected early Wednesday. Shares shed about 1% ahead of the open. The ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S (NYSE:NVO), reported Wednesday income and investment returns of 60 billion Danish kroner (around $8.68 billion) for ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Novo Nordisk (NVO) said Thursday Camilla Sylvest has decided to leave the company, after a distinguished career of 28 years ...

Bagsværd: Novo Nordisk HA has announced that Camilla Sylvest has decided to leave the company after a distinguished career of ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Novo Nordisk (NVO) ended the recent trading session at $67.10, demonstrating a -1.67% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of ...

Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and ...